CAR-T Archives | Page 3 of 13

BMS Makes a Bold Leap into CAR-T Buying Orbital Therapeutics for $1.5B

December 16, 2025 By Cade Hildreth, Founder & President Leave a Comment

On October 10th, 2025, Bristol Myers Squibb (BMS) announced its plan to acquire Orbital Therapeutics for 1.5 billion dollars in cash. This decisive move places BMS directly into the rapidly growing in vivo CAR T sector. Orbital Therapeutics, based in Cambridge, Massachusetts, has been advancing a next generation RNA platform that is designed to reprogram immune cells inside the body instead of relying on the traditional practice of engineering cells outside the body.

Central to the acquisition is Orbital’s lead candidate, OTX 201. This investigational treatment uses circular RNA delivered through lipid nanoparticles to encode a CD19 targeted CAR. The goal is to create CAR expressing cells directly within the patient. This approach could reshape the entire cell therapy landscape by eliminating complex external manufacturing steps. [Read more…]

What is CAR-T Cell Therapy? A New Way to Treat Cancer

November 3, 2025 By Cade Hildreth, Founder & President 1 Comment

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients across the globe. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.

For those confronting cancer, one crucial question often arises: What is CAR-T cell therapy? This guide answers the most common questions and explains how this innovative technology is transforming the future of cancer treatment.

[Read more…]

Is Storing Your Immune Cells Really Worth It?

September 1, 2025 By Cade Hildreth, Founder & President Leave a Comment

While cryopreserving cell tissue, stem cells and other blood products is nothing novel, the emerging field of immune cell banking certainly is. Immune cells are all the cells that make up your immune system, including T-cells, B-cells, NK cells, neutrophils cells, monocytes, dendritic cells, etc. They are your body’s first line of defense against infection and disease. New immunotherapies, such as CAR T-cell, CAR NK and dendritic cell therapies, are currently being developed to leverage those cells and offer new, experimental treatment options for cancer patients.

Storing immune cells may be a fairly new concept, but the potential benefits of storing immune cells have made forward-thinking, health-conscious individuals take notice. [Read more…]

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

August 19, 2025 By Cade Hildreth, Founder & President Leave a Comment

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science! [Read more…]

New Frontiers in Gene-Editing and Stem Cell Innovation – Interview with Dr. Chen-Tsai of Applied StemCell

February 20, 2025 By Cade Hildreth, Founder & President 3 Comments

I had the honor of interviewing Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), a fast growing biotechnology company in Milpitas, California. Specializing in gene-editing technologies and stem cell innovation, ASC offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.

In this fascinating interview, we discuss Dr. Yanru Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]